Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Arun Srivastava
University of Florida, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
AAVilon, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Next Generation of Recombinant AAV Serotype For Gene Therapy
The main aim of this proposal is to develop the next generation of vectors with which a therapeutic gene can be safely delivered to patients with a bleeding disorder called hemophilia B. These vectors are derived from a virus that causes no known disease, and is therefore, expected to be safer. The development of such a vector for the potential treatment and cure of hemophilia therefore has relevance to public health.
Filed on December 11, 2015.
Tell us what you know about Arun Srivastava's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Arun Srivastava filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Arun Srivastava | University of Florida | Conflict of Interest | AAVilon, Inc. | $0 - $4,999 |
Other search results for: “Arun Srivastava”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Arun Srivastava | University of Florida | Financial Disclosure | Nirvana Therapeutics, Inc. | |
| Arun Srivastava | University of Florida | Financial Disclosure | YEDA Research Institute of Gene and Cell Therapy | |
| Arun Srivastava | University of Florida | Financial Disclosure | AAVilonson | |
| Arun Srivastava | University of Florida | Financial Disclosure | Switch Bio, Inc. | |
| Arun Srivastava | University of Florida | Financial Disclosure | KASHX Bio | |
| Arun Srivastava | University of Florida | Financial Disclosure | Apgene Bio | |
| Arun Srivastava | University of Florida | Financial Disclosure | Visiting Advanced Joint Research Faculty (VAJRA), Department of Science and Technology | |
| Arun Srivastava | University of Florida | Financial Disclosure | Alexion Pharmaceuticals Inc. |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.